The Identity Crisis at the Heart of Medical Affairs
Medical Affairs — the function that translates clinical evidence for…
Mind vs. Machine in Asset Strategy
A well-informed asset strategy is an essential component of developing a novel…
The Right Forum, at the Right Time
Some people need to “think out loud.” Others are eager to get right to the…
100 Dots Connected: Reflecting on Eight Years of Conversations
The first edition of "Connecting the Dots" was published on September 29, 2017.…
Assuming the Role of Patient
As readers of The NemetzGroup newsletter know, we often use this space to consider progress in biopharma, new technologies, and ways emerging…
The “Forcing Function” of JPM
Biopharma companies need to balance many critical priorities, especially those that are pre-commercial.
BIO and Boston: The Global Stage and HLYB
Attending a large conference, medical congress, or trade show can be both exhausting and exhilarating. The decision to go in the first place depends…
Season of Transitions
Three notable transitions worthy of reflection at this point in time.
Medical Affairs Is Stepping Into the Future
The energy was palpable at the 2025 Medical Affairs Professional Society (MAPS) Global Annual Meeting. Conversations were expansive, workshops…
Rare Disease Day … The Power of Many Voices
Rare Disease Day unites this wide range of conditions under one shared umbrella, fostering a global community that amplifies the collective voice.
The Basics of Gratitude
Reflecting on the basics of gratitude can help us find perspective and appreciate the good in our lives.
The Power of Key Business Questions
In our biopharma world, we frequently hear the term “Key Business Questions (KBQs).” And while it’s often thrown around as a buzzword (or buzz…
The Underappreciated Value of New Product Planning
The value of New Product Planning (NPP) is often overlooked, but it plays a crucial role in the success of drug development projects. By…